Visby Medical™, a leading innovator in rapid at-home polymerase chain reaction (PCR) diagnostics, has announced the successful completion of a new financing round, raising approximately $55 million with the potential to increase to $65 million. The funding round was led by Catalio Capital Management, a prominent healthcare investment firm, and included continued support from existing investors such as ND Capital, Cedars Sinai Medical Center, Blue Water Life Science Advisors, Pitango Ventures, and renowned investor John Doerr.
The fresh capital will enable Visby Medical to accelerate the launch and commercialization of its recently FDA-authorized at-home Women’s Sexual Health Test. This advancement strengthens the company’s strategic focus on delivering highly accurate, laboratory-grade diagnostic testing directly to consumers, positioning Visby Medical as a leader in the growing at-home diagnostics market.
Catalio Capital Management’s involvement brings not only financial support but also strategic partnership to enhance Visby’s market reach and operational capabilities. As part of this investment, Catalio Partner Isaac Ro has joined Visby Medical’s board as an observer, bringing valuable industry insights and guidance.
Additionally, Visby Medical announced the appointment of Chuck Alpuche to its board as an independent director. Alpuche, currently Chief Operating Officer at Imperative Care and formerly EVP and COO at Insulet Corporation, also held senior leadership roles at PepsiCo. His extensive experience in scaling operations, manufacturing optimization, and cost efficiency will be instrumental in supporting Visby Medical’s growth and operational excellence.
“We are excited to partner with Catalio Capital Management as we pursue our mission to revolutionize healthcare through rapid, reliable at-home diagnostics that match the accuracy of traditional PCR testing,” said Adam de la Zerda, PhD, Founder and CEO of Visby Medical. “This funding empowers us to bring lab-accurate STI testing directly into the homes of consumers, offering greater convenience, privacy, and access to care.”
Isaac Ro highlighted the significance of Visby’s breakthrough technology, stating, “Visby Medical has created the first and only laboratory-grade at-home STI testing solution. We recognized its potential even before FDA clearance and are proud to support its mission to transform healthcare delivery.”
Chuck Alpuche added, “Visby’s FDA-authorized at-home test marks a pivotal shift in diagnostic accessibility. I look forward to contributing my operational expertise to help Visby scale manufacturing, reduce costs, and reach millions of consumers.”
The at-home Women’s Sexual Health Test, the first single-use, disposable PCR diagnostic of its kind, delivers results within 30 minutes via a connected smartphone app. Positive results prompt immediate connection with telemedicine providers for consultation and treatment. The product is scheduled for release through major direct-to-consumer channels starting July 2025.